Investors in RBT Biotech Company (BioTechnology Developments) will receive an offer from the Human Stem Cells Institute (HSCI, MOEX: ISKJ).
HSCI Ventures (a subsidiary of HSCI) has undertaken to buy back shares received by private subscription from investors at an investment price of RUB 236 per share. This offer significantly reduces the risk of losing investments in the biotech startup for investors.
Investors will be able to take advantage of the offer from April 20 to May 20, 2026, if the company does not conduct an IPO, does not pay dividends, or if its public offering is priced below RUB 200 per share.
According to HSCI’s Investment Director Dmitry Krasotkin: “RBT’s valuation seems attractive. We believe that investors will not need or want to use the offer as we implement the plans to develop vaccines and expand the portfolio of drugs. The company has a good portfolio, experienced management and strong partners. This means the company has a good chance of increasing its value in the coming years. The offer gives investors guarantees from HSCI that their investments will be safe while making participation in the venture deal more appealing.”
RBT is currently conducting a private offering on the Rounds investment platform. The underwriter of the offering is also the Alfa Investments service. The company plans to raise RUB 160 million. Investments will be used to expand the portfolio of vaccines developed by the company and to complete clinical trials of the influenza vaccine.
RBT is a company of the Human Stem Cell Institute group (HSCI, MOEX: ISKJ), a resident of Skolkovo and Medtech Moscow, the Moscow Center for Innovative Technologies in Healthcare Technopark.
Together with HSCI, RBT is developing a platform for the development of candidate antiviral vaccines based on surface recombinant proteins and spherical adjuvant particles. Previously, this platform was used to develop coronavirus vaccine Betuvax-Cov-2 and influenza vaccine TetraFluBET, as well as a pentavalent combination vaccine against influenza and coronavirus developed jointly with the Nacimbio pharmaceutical holding. RBT’s technology platform is aimed at making vaccines less reactogenic and minimizing their side effects, while maintaining the “protective” properties of vaccines, such as immunogenicity, at a high level. The company’s pipeline also includes a human papillomavirus vaccine.